瘤miRNA签名与II/III阶段黑色素瘤患者的结果有关
Jennifer M Wiggins1,2, Qiao Zhang2,3, Yian Zhang2,3
1Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
概括
微RNA (miRNA) 表达特征改善了黑色素瘤预后模型. 整合miRNA数据提高了 II 阶段黑色素瘤患者预测5年生存率的准确性,有助于治疗选择.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物标志物发现发现
背景情况:
- 患有II/III阶段黑色素瘤的患者表现出可变的结果,这表明超出瘤阶段的生物差异.
- 辅助疗法需要生物标志物来区分低风险和高风险黑色素瘤患者的复发和死亡率.
- 微RNAs (miRNAs) 是稳定的分子,在黑色素瘤中具有已被证明的预后作用,使它们成为有前途的生物标志物.
研究的目的:
- 调查将miRNA表达集成到预后模型中是否可以提高预测II和III阶段黑色素瘤患者5年生存率的准确性.
- 开发和验证基于miRNA的预后模型,用于黑色素瘤生存结果.
主要方法:
- 在InterMEL联盟中使用NanoStringmiRNA表达试验对II/III期患者的715种原发性黑色素瘤进行分析.
- 研究了miRNA表达与黑色素瘤特异性死亡的关联.
- miRNA签名被整合到临床预后模型中,用于生存预测.
主要成果:
- 在一个独立的测试组中,miRNA签名的整合改善了II阶段黑色素瘤接收器操作特征曲线 (AUC) 下的区域,从0.71 (仅临床因素) 到0.81 (临床加miRNA).
- 这代表了0.10 (95% CI:0.030.19) 的显著改善,用于II期患者的预测准确度.
- 在包括在分析中的III期黑色素瘤患者中观察到更为温和的改善.
结论:
- 将miRNA表达纳入初级黑色素瘤可以提高临床预后模型的准确性.
- 这种方法可能有助于选择黑色素瘤患者进行辅助治疗和临床试验.
- 微RNA分析提供了一种有价值的工具,用于完善黑色素瘤患者的风险分层.
更多相关视频
相关概念视频
02:39lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
02:17The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K